Your browser doesn't support javascript.
loading
Novel monoclonal antibody against integrin α3 shows therapeutic potential for ovarian cancer.
Ke, Feng-Yi; Chen, Wan-Yu; Lin, Ming-Chieh; Hwang, Yu-Chyi; Kuo, Kuan-Ting; Wu, Han-Chung.
Afiliación
  • Ke FY; Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.
  • Chen WY; Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Lin MC; Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.
  • Hwang YC; Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
  • Kuo KT; Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.
  • Wu HC; Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Cancer Sci ; 111(10): 3478-3492, 2020 Oct.
Article en En | MEDLINE | ID: mdl-32648337
Ovarian cancer has a high recurrence rate after platinum-based chemotherapy. To improve the treatment of ovarian cancer and identify ovarian cancer-specific antibodies, we immunized mice with the human ovarian carcinoma cell line, SKOV-3, and generated hybridoma clones. Several rounds of screening yielded 30 monoclonal antibodies (mAbs) with no cross-reactivity to normal cells. Among these mAbs, OV-Ab 30-7 was found to target integrin α3 and upregulate p53 and p21, while stimulating the apoptosis of cancer cells. We further found that binding of integrin α3 by OV-Ab 30-7 impaired laminin-induced focal adhesion kinase phosphorylation. The mAb alone or in combination with carboplatin and paclitaxel inhibited tumor progression and prolonged survival of tumor-bearing mice. Moreover, immunohistochemical staining of ovarian patient specimens revealed higher levels of integrin α3 in cancer cells compared with normal cells. By querying online clinical databases, we found that elevated ITGA3 expression in ovarian cancer is associated with poor prognosis. Taken together, our data suggest that the novel mAb, OV-Ab 30-7, may be considered as a potential therapeutic for ovarian cancer.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Integrina alfa3 / Anticuerpos Monoclonales Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Cancer Sci Año: 2020 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Integrina alfa3 / Anticuerpos Monoclonales Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Cancer Sci Año: 2020 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Reino Unido